by In2Pharma | Apr 11, 2025 | News
Luxembourg All Marketing Authorization Holders (MAHs) should have received a communication from the Luxembourg authorities regarding discrepancies in Marketing Authorization (MA) numbers for MRP/DCP and national procedure products in XEVMPD. This is part of an ongoing...
by In2Pharma | Apr 4, 2025 | News
The Netherlands Keuringsraad KOAGKAG can be consulted for advice with regard to promotional material and claims taking into account the current codes and guidelines for medicinal products, medical devices and health products. As the complexity of the questions...
by In2Pharma | Apr 4, 2025 | News
Europe In December 2024, a draft version of an amendment to the European legislation for pharmacovigilance activities (Implementing Regulation EU No. 520/2012) has been published by the European Commission. Public feedback was collected until the 15th of January 2025....
by In2Pharma | Apr 4, 2025 | News
Europe The new European Health Technology Assessment (HTA) regulation came into force in January. The main goals of this EU HTA regulation (EU HTAR) are: to improve and speed up the availability of innovative medicines and medical devices to patients across the EU; to...
by In2Pharma | Apr 4, 2025 | News
Belgium Pharma.be organised a yearly round table event to discuss and improve interactions and collaborations with patients. They have published their main findings on their website, but we will list the most relevant ones for you here below: * A new Q&A guidance...
by In2Pharma | Apr 4, 2025 | News
The Netherlands GMH has published an updated version of the GMH code. For example, the new maximum rates for service fees for this year, 2025, have been implemented. There were no alterations content-wise, but more explanation has been added on different points....
